Current status of irinotecan in lung cancer
Fukuoka, M.
Oncology 15(1 Suppl. 1): 6-7
2001
ISSN/ISBN: 0890-9091 PMID: 11221022 Document Number: 531347
Survival in lung cancer patients has not improved over the past 2 decades. Irinotecan (Camptosar, CPT-11), a semisynthetic analog of the quinoline-based alkaloid camptothecin, is one of several new drugs that have demonstrated promising activity in the treatment of lung cancer in recent years. This article gives a brief overview of the mechanism, development history, and current uses of this agent.
Document emailed within 1 workday
Related Documents
Flehinger, B.J.; Melamed, M.R. 1994: Current status of screening for lung cancer Chest Surgery Clinics of North America 4(1): 1-15Tanović, A.; Alfaro, V. 2004: Gefitinib: current status in the treatment of non-small cell lung cancer Drugs of Today 40(10): 809-827
Pathak, A.K.; Bhutani, M.; Mohan, A.; Guleria, R.; Bal, S.; Kochupillai, V. 2004: Non small cell lung cancer (NSCLC): current status and future prospects Indian Journal of Chest Diseases and Allied Sciences 46(3): 191-203
Konno, H.; Ohde, Y. 2019: Current Status of Limited Resection for Lung Cancer as Minimally Invasive Surgery Kyobu Geka. Japanese Journal of Thoracic Surgery 72(1): 51-56
Ichinose, Y.; Nakanishi, Y.; Goya, T. 2012: I. Current status and problems for clinical path of community network to lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(8): 1193-1196
Nishimura, M.; Sugiura, T.; Urata, A.; Ota, K. 1985: Current status in the treatment of inoperable non-small cell lung cancer (NSCLC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(1): 54-60
Socinski, M.A. 1999: The current status of adjuvant chemotherapy for resected non-small cell lung cancer Seminars in Oncology 26(5 Suppl 15: 27-33
Sandler, A.B. 2001: Irinotecan in small-cell lung cancer: the US experience Oncology 15(1 Suppl. 1): 11-12
Fukuoka, M.; Masuda, N.; Kudoh, S.; Negoro, S. 2000: Irinotecan in small-cell lung cancer--Japanese trials Oncology 14(7 Suppl. 5): 57-62
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Shima, T.; Masai, K.; Hishida, T.; Kaseda, K.; Hashimoto, K.; Takahashi, Y.; Otsuka, T.; Asamura, H. 2018: Role of Surgery in Multimodality Treatment for Non-small Cell Lung Cancer;Current Status and Future Perspectives Kyobu Geka. Japanese Journal of Thoracic Surgery 71(4): 244-248
Zhang, X-Ru.; Zhu, Y-Zhong.; Xiu, Q-Yu.; Han, F-Cai.; Liu, D-Qi.; Chu, D-Tong. 2006: Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 28(10): 777-779
Natale, R.B. 2003: Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer Oncology 17(7 Suppl. 7): 22-26
Hino, M.; Kobayashi, K.; Yoshimura, A.; Takeda, Y.; Hisakatsu, S.; Yoneda, S.; Gemma, A.; Moriya, H.; Kudoh, S. 2006: Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer Anticancer Research 26(6c): 4697-4703
Hirai, F. 2015: III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 940-943
Zhou, Z-Tao.; Wang, J-Wan. 2006: Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer Zhonghua Zhong Liu Za Zhi 28(7): 553-554
Ueda, A.; Hosokawa, A.; Ogawa, K.; Yoshita, H.; Mihara, H.; Ando, T.; Kajiura, S.; Fujinami, H.; Nishikawa, J.; Minemura, M.; Terada, M.; Kobayashi, T.; Horikawa, N.; Yabushita, K.; Note, M.; Sugiyama, T. 2013: Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum Anticancer Research 33(11): 5107-5111
Ryo, H.; Toyama, K.; Isobe, K.; Sugino, K.; Sano, G.; Yamada, H.; Hiroi, M.; Hojyo, T.; Kimura, K. 2003: A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(2): 237-242
Yamaguchi, M.; Fukuyama, Y.; Ichinose, Y. 2003: Current status of the neo-adjuvant and adjuvant therapy for the resectable non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(2): 203-208
Abou-Mourad, Y.; Otrock, Z.K.; Makarem, J.A.; Kattan, J.G.; Farhat, F.S.; Jalloul, R.; Mokaddem, W.T.; Ghosen, M.G.; Taher, A.T.; Chehal, A.A.; Shamseddine, A.I. 2008: Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study Le Journal Medical Libanais. Lebanese Medical Journal 56(1): 16-21